There have been a few developments supporting that
Tekmira’s campaign to re-gain control over its technology from Alnylam and be
recognized for its scientific accomplishments is as strong as ever (see 'Tekmira Tells Alnylam 'Enough is Enough'').
Notably, based on LinkedIn entries, it appears as if key
personnel in Alnylam’s RNAi delivery group got the axe during the latest round of lay-offs at the company. Among those is Mark Tracy, former President of the Controlled Release Society and who according to LinkedIn
'Built and led a multi-national RNAi delivery research and development alliance of industry and academic partners that enabled human clinical proof of concept for RNAi and a growing pipeline of clinical products. Matrixed-managed an international multi-department, mutli-organizational team of over 50 FTE. Directed technology assessment and due diligence activities. Headed delivery project and alliance management and business and financial planning.'
which would arguably make him one of the central players in Alnylam's relationship with Tekmira (note the emphasis on 'multi-national/international'). This should further fuel takeover speculations as in a merger there certainly wouldn’t be room
left for liposomal delivery research organizations at both Tekmira and Alnylam. It would further be consistent with the
recent $85M dollar fund-raising by Alnylam that followed the take-over script.
Perhaps symbolizing the shifting legal fortunes of the companies, a
Court Order has just gone out declaring Tekmira (Protiva) the Senior Party,
and Alnylam the Junior Party in the ALN-VSP02 Interference. As you will remember, the Interference, an
intriguing side-show to the Alnylam-Tekmira conflict, was declared by the USPTO
when it found that Alnylam’s issued ALN-VSP patent (US 7718629) and a patent application
by Tekmira were too close in nature for them to co-exist. The goal of the Interference now
is to determine who first invented the subject matter that both patent
(applications) are claiming.
Based on important decisions on Motions by the companies in March,
decisions which will set the tone for the rest of the proceedings, it
already looked like Alnylam’s case stood on very weak grounds. Still, with
Alnylam, as the patent holder, being considered the 'Senior Party', and Tekmira as the competing patent applicant being considered the ‘Junior Party’, Tekmira faced certain procedural disadvantages, including burden of
proof with regard to claiming temporal priority in the upcoming phase of the Interference.
However, in what must be a very satisfying turn of events for
Tekmira, the judge now has agreed with the small Vancouver-based company's request that it actually should be the Senior Party, and widely recognized RNAi
behemoth Alnylam only the Junior Party:
This not only makes it more likely that Alnylam will lose
control over the liver cancer drug candidate at stake, but it is highly
symbolic for what could unfold over the next 6 months or so leading up to their
$1B day in court. If it comes to that, the
very existence of Alnylam will be in question. Another question is whether the music will still be playing then.
